BMY-14802 — разлика између измена
Садржај обрисан Садржај додат
м . |
м Бот: по захтеву Вукса (lat) |
||
| (Није приказано 18 међуизмена 4 корисника) | |||
| Ред 6: | Ред 6: | ||
| image2 = |
| image2 = |
||
| width2 = |
| width2 = |
||
| CAS_number_Ref = {{cascite|correct|}} |
|||
| CAS_number = 105565-55-7 |
| CAS_number = 105565-55-7 |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = 108046 |
| PubChem = 108046 |
||
| IUPHAR_ligand = |
|||
| ChEMBL_Ref = |
|||
| ChEMBL = |
|||
| DrugBank_Ref = |
|||
| DrugBank = |
|||
| C=18 | H=22 | F=2 | N=4 | O=1 |
| C=18 | H=22 | F=2 | N=4 | O=1 |
||
| molecular_weight = 348.389 -{g/mol}- |
| molecular_weight = 348.389 -{g/mol}- |
||
| smiles = c1cc(F)ccc1C(O)CCCN2CCN(CC2)c3ncc(F)cn3 |
| smiles = c1cc(F)ccc1C(O)CCCN2CCN(CC2)c3ncc(F)cn3 |
||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|||
| InChI = |
|||
| |
| StdInChI = |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChIKey = |
|||
| melting_point = |
| melting_point = |
||
| melting_high = |
| melting_high = |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Ред 33: | Ред 44: | ||
}} |
}} |
||
-{'''BMY-14802'''}- je lek sa [[antipsihotici|antipsihotičkim]] dejstvom. On je [[Antagonist (farmakologija)|antagonist]] [[sigma receptor]]a, i agonist [[5-HT1A receptor|5-HT<sub>1A</sub>]] receptora.<ref name="pmid8232511">{{cite journal | |
-{'''BMY-14802'''}- je lek sa [[antipsihotici|antipsihotičkim]] dejstvom. On je [[Antagonist (farmakologija)|antagonist]] [[sigma receptor]]a, i agonist [[5-HT1A receptor|5-HT<sub>1A</sub>]] receptora.<ref name="pmid8232511">{{cite journal |vauthors=Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG |title=A role for sigma binding in the antipsychotic profile of BMY 14802? |journal=NIDA Research Monograph |volume=133 |issue= |pages=125–57 |year=1993 |pmid=8232511 |doi= |url=}}</ref><ref name="pmid9435153">{{cite journal |vauthors=Vanecek SA, Essman WD, Taylor DP, Woods JH |title=Discriminative stimulus characteristics of BMY 14802 in the pigeon |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=284 |issue=1 |pages=1–9 |year=1998 |pmid=9435153 |doi= |url=}}</ref><ref name="pmid19052726">{{cite journal |vauthors=Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M |title=Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice |journal=Psychopharmacology |volume=203 |issue=4 |pages=781–92 |year=2009 |pmid=19052726 |doi=10.1007/s00213-008-1425-z |url=https://archive.org/details/sim_psychopharmacology_2009-05_203_4/page/781}}</ref><ref name="pmid19283364">{{cite journal |vauthors=Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP |title=The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism |journal=Psychopharmacology |volume=204 |issue=4 |pages=743–54 |year=2009 |pmid=19283364 |pmc=2845289 |doi=10.1007/s00213-009-1505-8 |url=https://archive.org/details/sim_psychopharmacology_2009-07_204_4/page/743}}</ref> |
||
== |
== Reference == |
||
{{reflist |
{{reflist}} |
||
{{-}} |
|||
{{Serotonergici-lat}} |
|||
{{serotonergici-lat}} |
|||
{{modulatori sigma receptora-lat}} |
|||
| ⚫ | |||
{{Podnožje|lat=da|Medicina|Hemija}} |
|||
[[Категорија:Сигма антагонисти]] |
[[Категорија:Сигма антагонисти]] |
||
| Ред 46: | Ред 63: | ||
[[Категорија:Пиперазини]] |
[[Категорија:Пиперазини]] |
||
[[Категорија:Алкохоли]] |
[[Категорија:Алкохоли]] |
||
| ⚫ | |||
Тренутна верзија на датум 7. март 2024. у 23:11
 | |
| IUPAC ime | |
|---|---|
1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol | |
| Identifikatori | |
| CAS broj | 105565-55-7  |
| ATC kod | none |
| PubChem | CID 108046 |
| Hemijski podaci | |
| Formula | C18H22F2N4O |
| Molarna masa | 348.389 g/mol |
| |
BMY-14802 je lek sa antipsihotičkim dejstvom. On je antagonist sigma receptora, i agonist 5-HT1A receptora.[1][2][3][4]
Reference
[уреди | уреди извор]- ^ Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). „A role for sigma binding in the antipsychotic profile of BMY 14802?”. NIDA Research Monograph. 133: 125—57. PMID 8232511.
- ^ Vanecek SA, Essman WD, Taylor DP, Woods JH (1998). „Discriminative stimulus characteristics of BMY 14802 in the pigeon”. The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 1—9. PMID 9435153.
- ^ Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (2009). „Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice”. Psychopharmacology. 203 (4): 781—92. PMID 19052726. doi:10.1007/s00213-008-1425-z.
- ^ Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (2009). „The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism”. Psychopharmacology. 204 (4): 743—54. PMC 2845289
. PMID 19283364. doi:10.1007/s00213-009-1505-8.
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
